These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32982275)

  • 1. Three Novel
    Li H; Yu T; Lin Y; Xie Y; Feng J; Huang M; Guo A; Liu X; Yin Z
    Onco Targets Ther; 2020; 13():7941-7948. PubMed ID: 32982275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
    Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
    Front Oncol; 2021; 11():733276. PubMed ID: 34760695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report.
    Li J; Liu X; Yuan C
    Mol Clin Oncol; 2018 Sep; 9(3):321-324. PubMed ID: 30112177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.
    Xu CW; Lei L; Wang WX; Lin L; Zhu YC; Wang H; Miao LY; Wang LP; Zhuang W; Fang MY; Lv TF; Song Y
    Transl Oncol; 2020 Sep; 13(9):100791. PubMed ID: 32492620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with
    Kuang Y; Wang J; Xu P; Zheng Y; Bai L; Sun X; Li Z; Gan R; Li H; Ke Z; Tang K
    Ann Transl Med; 2021 Aug; 9(16):1354. PubMed ID: 34532491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation.
    Zhu Y; Tang J; Li X; Qin T; Wei Y
    Onco Targets Ther; 2020; 13():10447-10451. PubMed ID: 33116624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports.
    Meng Y; Li X; Zhang L; Ye M
    Front Oncol; 2023; 13():1129629. PubMed ID: 37795433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.
    Qin BD; Jiao XD; Yuan LY; Liu K; Wang Z; Qin WX; Zang YS
    Onco Targets Ther; 2018; 11():4739-4745. PubMed ID: 30127622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report.
    Liu L; Lizaso A; Mao X; Yang N; Zhang Y
    Transl Lung Cancer Res; 2020 Feb; 9(1):144-147. PubMed ID: 32206561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
    Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
    BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ma L; Chen R; Wang F; Ma LL; Yuan MM; Chen RR; Liu J
    Ann Transl Med; 2019 May; 7(9):207. PubMed ID: 31205925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report.
    Hu XY; Fei YC; Zhou WC; Zhu JM; Lv DL
    World J Clin Cases; 2021 Apr; 9(11):2627-2633. PubMed ID: 33889629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.
    Cekay M; Arndt PF; Dumitrascu R; Savai R; Braeuninger A; Gattenloehner S; Steiner D; Roller F; Tello K; Hattar K; Seeger W; Sibelius U; Grimminger F; Eul B
    Front Oncol; 2023; 13():1182391. PubMed ID: 37655099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Response To Osimertinib In
    Li H; Yu T; Huang M; Guo A; Qian X; Yin Z
    Onco Targets Ther; 2019; 12():7785-7790. PubMed ID: 31571928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
    Le T; Gerber DE
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.